Warning letter
Ningbo Smart Pharmaceutical Co. Ltd. [ARCHIVED]: warning letter of Mar 30, 2011
FDA warning letter 163312 · Center for Drug Evaluation and Research
Key facts
| Reference number | 163312 |
|---|---|
| Company | Ningbo Smart Pharmaceutical Co. Ltd. [ARCHIVED] |
| Subject | CGMP/Adulterated |
| Issue date | Mar 30, 2011 |
| Posted date | Mar 30, 2011 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| Inspection city | Ningbo |
| Inspection start date | Oct 25, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: